X
Neurofibromatosis treatment granted orphan status by EMA
https://pharmaphorum.com/news/nf1-treatment-granted-orphan-status-ema/
Merck Inc
Merck’s failure casts gloom over remaining BACE Alzheimer’s drugs
But trial in patients in early stage of the disease continues.
Opdivo still clear immunotherapy leader despite Keytruda gains
Immunotherapy takes on rivals from Roche and BMS.
BMS suffers further setback in lung cancer
No fast approval for immunotherapy combo in first line use.
Merck soars on Keytruda combination filing
Approval by May could put Keytruda in pole position
Sanofi Pasteur and MSD end vaccines joint venture
Companies end collaboration after more than 20 years.
2016 saw slump in FDA drug approvals, but 2017 could be return to form
FDA approvals could rebound in 2017 – but concerns about big pharma R&D productivity won’t go away.
Keytruda set for first line lung cancer use in EU
MSD drug will not face competition from BMS rival in this use.
1 2